Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings [Yahoo! Finance]
AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics [Yahoo! Finance]
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics